---
document_datetime: 2023-09-21 17:14:56
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps/vistide-epar-procedural-steps-taken-authorisation_en.pdf
document_name: vistide-epar-procedural-steps-taken-authorisation_en.pdf
version: success
processing_time: 0.3747067
conversion_datetime: 2025-12-24 20:42:20.961933
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## I. BACKGROUND INFORMATION ON THE PROCEDURE

## 1. Submission of the dossier

The  company  Gilead  Sciences  Limited,  UK  submitted  to  the  EMEA  on  28  December  1995  an application for Marketing  Authorisation for Vistide through the centralised procedure. After agreement by the CPMP in July 1995 this medicinal product is referred to List B in the Annex of the Council Regulation EEC No 2309/93, indent 7 as it contains a new active substance.

The Rapporteur and Co-Rapporteur appointed by the CPMP were:

Rapporteur:

Prof. J.A. Guimarães Morais

Co-Rapporteur:

Dr D. Jefferys

Licensing status: Vistide has been approved in the United States of America on 26 June 1996. 2. Steps taken for the assessment of the product · An  application  for  Marketing  Authorisation  for  Vistide  was  submitted  to  the  EMEA  on 28 December 1995. The centralised procedure started on 16 January 1996. · The Rapporteur's assessment report was circulated to all CPMP members on 15 April 1996. · The Co-Rapporteur's assessment report was circulated to all CPMP members on 15 April 1996. · The Rapporteur's and Co-Rapporteur's assessment reports and the comments from other CPMP members were discussed during the CPMP meeting in May 1996. · An inspection  for  the  manufacturing  facilities  of  the  finished  pharmaceutical  dosage  form  at Ben  Venue  Laboratories,  Bedford,  Ohio,  United  States  of  America  was  carried  out  by  the Inspection Service of the United Kingdom on 15 and 16 April 1996. · The CPMP consolidated List of Questions was adopted on 22 May 1996. · The responses to the consolidated List of Questions were provided on 27 August 1996. · The joint Rapporteur's and Co-Rapporteur's assessment report on the responses provided by the applicant was sent to all CPMP members on 21 October 1996. · A  break  out  session  was  held  during  the  CPMP  in  November  1996  in  order  to  discuss  the wording of the therapeutic indication. · The  CPMP  issued  on  18  December  1996  a  positive  opinion  for  granting  a  Marketing Authorisation for Vistide. The CPMP opinion was forwarded, in all official languages of the European Union, to the European Commission which adopted the corresponding Decision on 23 April 1997. Medicinal product no longer authorised